Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Roche to acquire immuno-oncology company Tusk Therapeutics

Switzerland’s Roche is buying UK-based Tusk Therapeutics in a deal that could hit EUR 655 million.

Read More »

J&J Terminates Imetelstat Collaboration with Geron

Johnson & Johnson and Geron had teamed up to develop and commercialize imetelstat, a first-in-class telomerase inhibitor, for myelofibrosis and myelodysplastic syndromes.

Read More »

Brooks Automation Moves Further into Life Sciences with $450 Million Deal for Genewiz Group

Brooks Automation will increase the automation and cryogenics specialist’s toehold in the life sciences industry with a $450 million all-cash acquisition of genomic services group Genewiz.

Read More »

Celgene Ends Navicixizumab Licensing Deal with OncoMed

Shares of OncoMed Pharmaceuticals fell after the company announced that Celgene walked away from a deal to license the bispecific antibody navicixizumab.

Read More »

Amicus Therapeutics Buys Celenex

Amicus Therapeutics inked a definitive agreement for 10 gene therapy programs licensed from Nationwide Children’s Hospital through the acquisition of Celenex.

Read More »

Molecular Templates, Takeda Strike MM Deal

Shares of Molecular Templates were up more than 52 percent after announcing a deal with Takeda that could be worth up to $632 million to develop CD38-targeted engineered toxin bodies.

Read More »

MannKind, United Therapeutics Ink $95 Million+ Deal

MannKind Corp. and United Therapeutics Corp. signed a worldwide exclusive license and collaboration deal to develop and commercialize a dry powder formulation of treprostinil being studied in clinical trials to treat pulmonary arterial hypertension.

Read More »

Emergent BioSolutions to buy Narcan maker Adapt Pharma

Emergent BioSolutions will buy privately held Adapt Pharma, beefing up its portfolio with Narcan, the only FDA-approved needle-free emergency opioid overdose treatment.

Read More »

Bayer teams up with Evotec, Haplogen

Collaboration partners Evotec AG and Haplogen GmbH announced that Haplogen will enter into a multi-year drug discovery and development deal with Bayer AG to focus on pulmonary diseases.

Read More »

Orchard raises $150 million to expand

Orchard Therapeutics raised a further $150 million to fund the biotech company’s work in gene therapy, building on earlier fundraisings worth more than $140 million.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!


Ad Right Bottom